Loading...
•
Dec 31, 2021
Amgen Q4 2021 Earnings Report
Amgen's financial performance saw revenue increase, driven by other revenue from the Lilly collaboration, while product sales experienced a slight decrease. GAAP EPS increased, influenced by revenue growth and fewer shares outstanding. The company's pipeline advancements and strategic collaborations are expected to support long-term growth.
Key Takeaways
Amgen reported a 3% increase in total revenues for Q4 2021, reaching $6.8 billion, driven by increased Other Revenue from the Eli Lilly and Company (Lilly) COVID-19 manufacturing collaboration. GAAP earnings per share (EPS) increased 22% to $3.36 in the fourth quarter driven by increased revenues and lower weighted average shares outstanding.
Total revenues increased by 3% to $6.8 billion, driven by increased Other Revenue from the Lilly collaboration.
GAAP EPS increased by 22% to $3.36, influenced by revenue growth and fewer shares outstanding.
Non-GAAP EPS increased by 26% to $4.36, driven by increased revenues, decreased other expense and the impact of fewer weighted average shares outstanding.
Prolia sales increased 17% year-over-year.
Amgen
Amgen
Amgen Revenue by Segment
Revenue by Segment
Repatha Revenue
CapyFin.comEVENITY Revenue
CapyFin.comProlia Revenue
CapyFin.comOtezla Revenue
CapyFin.comEnbrel Revenue
CapyFin.comKyprolis Revenue
CapyFin.comXGEVA Revenue
CapyFin.comVectibix Revenue
CapyFin.comNplate Revenue
CapyFin.comBLINCYTO Revenue
CapyFin.comAranesp Revenue
CapyFin.comParsabiv Revenue
CapyFin.comAMJEVITA / AMGEVITA Revenue
CapyFin.comMVASI Revenue
CapyFin.comNeulasta Revenue
CapyFin.comOther products Revenue
CapyFin.com Forward Guidance
Amgen provided financial guidance for 2022 and longer-term financial guidance through the end of the decade.
Positive Outlook
- Plans to grow the many innovative medicines and biosimilars in the Company’s currently marketed portfolio
- Advance numerous potential new medicines through its pipeline
- Capitalize on advances in science and technology to build a set of differentiated discovery research capabilities.
Revenue & Expenses
Visualization of income flow from segment revenue to net income